Seres Therapeutics (MCRB) Fundamentals 2026 — Revenue Analysis | SniperIQ
Seres Therapeutics (MCRB) is a US-listed Healthcare company in Biotechnology with a market capitalization of $51M, trading at $5.24 on the NASDAQ. This SniperIQ fundamentals page covers Seres Therapeutics's valuation, profitability (net margin -4088.8%), revenue ($789,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Seres Therapeutics's market cap?
Seres Therapeutics (MCRB) has a market capitalization of approximately $51M, trading at $5.24 on the NASDAQ. Market cap moves with the live share price.
What is Seres Therapeutics's P/E ratio?
Seres Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Seres Therapeutics?
Seres Therapeutics runs a net profit margin of -4088.8%, a gross margin of -20.9%, and an operating margin of -7641.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Seres Therapeutics generate?
Seres Therapeutics reported revenue of $789,000 for fiscal year 2025, with net income of $6M and earnings per share (EPS) of 0.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Seres Therapeutics pay a dividend?
Seres Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Seres Therapeutics financially healthy?
Seres Therapeutics carries a debt-to-equity ratio of 3.04x and a current ratio of 1.65x, with a market beta of 0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Seres Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Seres Therapeutics (MCRB) the key facts are: market cap $51M, revenue $789,000, 52-week range 5-29.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Seres Therapeutics's full fundamentals live
Get Seres Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.